Back on the grid… rested and ready. Grin.
And while in transit yesterday, AARP filed its amicus brief — explaining why Merck’s purported federal suit ought to be dismissed, in DC.
There simply is no legal US property right — to avoid at least listening to government / customer initiated price negotiations, before they even begin. In any event, here is that filing, from yesterday, and a bit:
…[T]he list price of Januvia has increased by 275 percent since it entered the market in 2006, and the drug has accounted for $21.6 billion in Medicare Part D spending between 2017 and May 2023….
Merck seeks to protect the pharmaceutical industry’s ability to charge unreasonable and astronomical prices at the expense of what people with chronic conditions need to survive. [Merck’s] efforts threaten the financial health of Medicare….
This is a medicine (Januvia) that, in many many cases, the lack of which will lead to… death, for diabetics. One that Merck has been profiting from, for 17 years already — likely to the tune of over $60 billion, life to date. C’mon, man!
नमस्ते
Powerline Lies... 